Warrants series TO 3
Following the rights issue completed on 25 April 2023 Qlife Holding AB has issued 622,351,940 warrants series TO3. One (1) warrant series TO 3 entitles the rights to subscribe for one (1) new share in the Company at a subscription price of SEK 0.11. This means that upon full exercise of all warrants, Qlife will receive additional proceeds of a maximum of approximately SEK 68 million before transaction costs. Subscription of shares by exercise of warrants will take place during the period 11 – 29 September 2023.
Warrants series TO 2
Following the rights issue completed on 17 October 2022 Qlife Holding AB has issued 7,587,609 warrants (TO 2). One (1) warrant entitle to subscribe for 1,08 new share at an exercise price corresponding to 70 percent of the volume-weighted average price of the Company’s share during the period from and including 22 May 2023 up to and including 2 June 2023, however, not less than the share’s quota value and not more than SEK 9.27 per share. This means that the additional proceeds that may be added upon exercise of the warrants may not exceed a maximum of approximately SEK 75.9 million before transaction costs. Subscription of shares by exercise of warrants takes place during the period 7 – 21 June 2023.
Warrants series TO 1
On 2 June, 2021, Qlife Holding AB announced the outcome of the exercise of warrants of serie TO 1 that were issued in connection with the Company's issue of units in February 2020. In total, 4,356,436 warrants of series TO 1 were exercised, corresponding to approximately 97.4 percent of total number of outstanding warrants, for subscription of 2,178,218 shares at a subscription price of SEK 17.50 per share. Through the exercise of warrants, Qlife will receive approximately SEK 38.1 million before issuing costs amounting to approximately SEK 1.4 million. The exercise period for the warrants of series TO 1 took place from May 3, 2021 up to and including May 31, 2021.